Sugi Predict

Sugi Predict / Compounds / SCHEMBL1536282

SCHEMBL1536282

SCHEMBL1536282

CCOc1ccccc1C=CC(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGER1 P34995 1/20 0.66
▸ PTGER4 P35408 1/20 0.66
▸ PTGER3 P43115 1/20 0.66
▸ PTGER2 P43116 1/20 0.66
▸ SMN1; SMN2 Q16637 3/20 0.63
▸ LMNA P02545 3/20 0.63
▸ MAPT P10636 1/20 0.63
▸ ATM Q13315 1/20 0.63
▸ HTT P42858 1/20 0.61
▸ GAA P10253 3/20 0.57
▸ AR P10275 1/20 0.56
▸ KDM4E B2RXH2 6/20 0.55
▸ ALDH1A1 P00352 2/20 0.55
▸ GLA P06280 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ NFE2L2 Q16236 2/20 0.53
▸ KMT2A Q03164 1/20 0.52
▸ CA1 P00915 1/20 0.51
▸ CA2 P00918 1/20 0.51
▸ NFKB1 P19838 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1536281 1.00 PTGER1 (0.66) PTGER1PTGER4PTGER3PTGER2SMN1; SMN2
SCHEMBL14843147 0.89 PTGER1 (0.64) PTGER1PTGER4PTGER3PTGER2SMN1; SMN2
SCHEMBL1356220 0.89 PTGER1 (0.64) PTGER1PTGER4PTGER3PTGER2SMN1; SMN2
SCHEMBL5078092 0.87 PTGER1 (0.62) PTGER1PTGER4PTGER3PTGER2SMN1; SMN2
SCHEMBL9716888 0.87 PTGER1 (0.62) PTGER1PTGER4PTGER3PTGER2SMN1; SMN2
SCHEMBL11341981 0.87 KDM4E (0.68) PTGER1PTGER4PTGER3PTGER2SMN1; SMN2
SCHEMBL11327707 0.87 KDM4E (0.68) PTGER1PTGER4PTGER3PTGER2SMN1; SMN2
SCHEMBL3689444 0.87 PTGER1 (0.52) PTGER1PTGER4PTGER3PTGER2SMN1; SMN2
SCHEMBL5178116 0.86 PTGER1 (0.61) PTGER1PTGER4PTGER3PTGER2SMN1; SMN2
SCHEMBL8330993 0.86 MAPT (0.80) SMN1; SMN2LMNAMAPTATMAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117430125-B Preparation method and application of manganese doped mesoporous structure-containing acidic Beta zeolite molecular sieve 常州大学 2025-03-21 — — CN claimed
CN-117430125-A Preparation method and application of manganese doped mesoporous structure-containing acidic Beta zeolite molecular sieve 常州大学 2024-01-23 — — CN claimed
CN-117430125-B Preparation method and application of manganese doped mesoporous structure-containing acidic Beta zeolite molecular sieve 常州大学 2025-03-21 — — CN disclosed
CN-117430125-A Preparation method and application of manganese doped mesoporous structure-containing acidic Beta zeolite molecular sieve 常州大学 2024-01-23 — — CN disclosed
CN-110769864-B Gel deodorant 艾饰庭株式会社 2021-05-07 — — CN disclosed
CN-110769864-A Gel deodorant 艾饰庭株式会社 2020-02-07 — — CN disclosed
CN-106795327-B Resin composition and optical compensation film using the same 东曹株式会社 2019-08-30 — — CN disclosed
US-10392398-B2 Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERSITY (US) 2019-08-27 — — US disclosed
US-20180051033-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS TRUSTEES OF BOSTON UNIVERSITY (US) 2018-02-22 — — US disclosed
US-9815845-B2 Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERSITY (US) 2017-11-14 — — US disclosed
US-9802948-B2 Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics TRUSTEES OF BOSTON UNIVERISTY (US) 2017-10-31 — — US disclosed
CN-1668297-A Hepatitis C virus inhibitors BRISTOL MYERS SQUIBB CO (US) 2005-09-14 — — CN disclosed
US-20050004174-A1 Antibacterial agents GORDEEV MIKHAIL F (US) 2005-01-06 — — US disclosed
US-6562844-B2 Attaching an olefin to a solid support; oxidizing the olefin to provide an epoxide functionality; opening the epoxide with an amine to form an amino alcohol; cyclizing the amino alcohol using a phosgene equivalent PHARMACIA & UPJOHN COMPANY 2003-05-13 — — US disclosed
US-6531470-B1 Antimicrobial compounds PHARMACIA & UPJOHN COMPANY 2003-03-11 — — US disclosed
US-6239152-B1 Oxazolidinone combinatorial libraries, compositions and methods of preparation PHARMACIA & UPJOHN COMPANY 2001-05-29 — — US disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 — — EP disclosed
CN-1288462-A Oxazolidinone combinatorial libraries, compositions and method of prepn. UPJOHN CO (US) 2001-03-21 — — CN disclosed
WO-2000007993-A1 SUBSTITUTED ISOQUINOLEINES AND THEIR USE AS ANTICONVULSIVANTS SMITHKLINE BEECHAM PLC (GB) 2000-02-17 — — WO disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180051033-A1 INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS GTF2F1, HDGF, GTF3C5 PTGER1 4606/4885PTGER4 4400/4885PTGER3 4469/4885
US-20050004174-A1 Antibacterial agents PAICS, OXA1L, PNKP PTGER1 3918/4885PTGER4 3480/4885PTGER3 3782/4885
US-10392398-B2 Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics GTF2F1, HDGF, GTF3C5 PTGER1 4606/4885PTGER4 4400/4885PTGER3 4469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.